207 related articles for article (PubMed ID: 29274130)
1. A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia.
Miao J; Leblebjian H; Scullion B; Parnes A
Am J Hematol; 2018 Aug; 93(4):E86-E88. PubMed ID: 29274130
[No Abstract] [Full Text] [Related]
2. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Haematologica; 2018 Apr; 103(4):e169-e172. PubMed ID: 29242295
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
4. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
5. Romiplostim: new drug. Thrombocytopenic purpura: for selected patients, with close monitoring.
Prescrire Int; 2009 Dec; 18(104):246. PubMed ID: 20020571
[No Abstract] [Full Text] [Related]
6. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
8. Romiplostim for management of chemotherapy-induced thrombocytopenia.
Parameswaran R; Lunning M; Mantha S; Devlin S; Hamilton A; Schwartz G; Soff G
Support Care Cancer; 2014 May; 22(5):1217-22. PubMed ID: 24414994
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor agonists can be used temporarily with patients suffering from refractory chronic lymphocytic leukemia-associated immunologic thrombocytopenia.
Sinisalo M; Sankelo M; Itälä-Remes M
Leuk Lymphoma; 2011 Apr; 52(4):724-5. PubMed ID: 21323511
[No Abstract] [Full Text] [Related]
10. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma.
Demeter J; Istenes I; Fodor A; Paksi M; Dombi P; Valasinyószki E; Csomor J; Matolcsy A; Nagy ZG
Pathol Oncol Res; 2011 Mar; 17(1):141-3. PubMed ID: 20628840
[TBL] [Abstract][Full Text] [Related]
11. Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia.
Berthelot-Richer M; Boilard B; Morin A; Bolduc B; Beauregard P; Kotb R
Transfusion; 2012 Apr; 52(4):739-41. PubMed ID: 22082044
[TBL] [Abstract][Full Text] [Related]
12. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
[TBL] [Abstract][Full Text] [Related]
13. Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia.
D'Arena G; Cascavilla N
Leuk Lymphoma; 2011 Apr; 52(4):701-4. PubMed ID: 21171868
[No Abstract] [Full Text] [Related]
14. Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment.
Cantoni N; Heizmann M; Bargetzi M
Br J Haematol; 2012 Jun; 157(5):639-41. PubMed ID: 22329466
[No Abstract] [Full Text] [Related]
15. Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia.
Aslam MI; Cardile AP; Crawford GE
J Int Assoc Provid AIDS Care; 2014; 13(1):22-3. PubMed ID: 24036490
[TBL] [Abstract][Full Text] [Related]
16. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
Shinohara K; Kambara N
Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
[TBL] [Abstract][Full Text] [Related]
17. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
18. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
Al-Samkari H; Van Cott EM; Kuter DJ
Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
[TBL] [Abstract][Full Text] [Related]
19. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience.
Pasquet M; Aladjidi N; Guiton C; Courcoux MF; Munzer M; Auvrignon A; Lutz P; Ducassou S; Leroy G; Munzer C; Leverger G;
Br J Haematol; 2014 Jan; 164(2):266-71. PubMed ID: 24152194
[TBL] [Abstract][Full Text] [Related]
20. Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.
Le Rhun E; Devos P; Houillier C; Cartalat S; Chinot O; Di Stefano AL; Lepage C; Reyns N; Dubois F; Weller M
Neurology; 2019 Nov; 93(19):e1799-e1806. PubMed ID: 31586022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
